Evidence map›Paper›PMID 34845315›Full record

ArticleLeukemia2022

Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia.

Sunisa Kongkiatkamon, Simona Pagliuca, Vera Adema, Yasunobu Nagata, Cassandra M Kerr, Wencke Walter, Hassan Awada, Stephan Hutter, Carmelo Gurnari, Heesun J Rogers and 5 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 4 countries.

Sunisa KongkiatkamonDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-3273-6069
Simona PagliucaDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-4688-2478
Vera AdemaDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
Yasunobu NagataDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
Cassandra M KerrDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
Wencke WalterMLL Munich Leukemia Laboratory, Munich, Germany.
Hassan AwadaDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
Stephan HutterMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0003-2432-8898
Carmelo GurnariDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-6829-5544
Heesun J RogersDepartment of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-8491-224X
Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany.
Yogen SaunthararajahDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-9757-1031
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Valeria VisconteDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-2993-1509
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.ORCID http://orcid.org/0000-0002-6837-4346
Cleveland Clinic · USMunich Leukemia Laboratory (Germany) · DE

Funding

Therapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7M
Novel Spliceosomal Defects in Myelodysplastic SyndromesR01HL132071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2016 to 2019
$2.4M
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic TargetR01HL123904 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI JANKOWSKY, ECKHARD, MACIEJEWSKI, JAROSLAW P. · 2015 to 2018
$2.1M
Investigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9M
NHLBI NIH HHS R01 HL118281NHLBI NIH HHS R01 HL123904NHLBI NIH HHS R01 HL132071NHLBI NIH HHS R35 HL135795
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myeloproliferative DisordersNeoplasmsCREB-Binding ProteinE1A-Associated p300 ProteinHistone AcetyltransferasesHumansCREB-Binding ProteinCREBBP protein, humanE1A-Associated p300 ProteinEP300 protein, humanHistone Acetyltransferases

Identifiers

PMID34845315
OpenAlexW3214929860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.